Grifols (GRFS) Receivables - Other (2009 - 2025)
Grifols' (GRFS) quarterly Receivables - Other came in at $158.3 million in Q4 2025, up 89.93% YoY from $83.4 million in Q4 2024, and up 89.93% on a QoQ basis from $83.4 million in Q4 2024.
Grifols (GRFS) Receivables - Other (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Receivables - Other data on file, last reported at $158.3 million in Q4 2025.
- Quarterly Receivables - Other rose 89.93% year-over-year to $158.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158.3 million (up 89.93% YoY) and the FY2025 annual result came in at $158.3 million, up 89.93% from the prior year.
- Receivables - Other grew to $158.3 million in Q4 2025, from $83.4 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $158.3 million in Q4 2025 to a low of $74.7 million in Q4 2022.
- A 5-year average of $109.5 million and a median of $83.4 million in 2024 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2021 — Receivables - Other soared 8636.98% — and 2022, when it tumbled 50.47%.
- Tracing GRFS's Receivables - Other over 5 years: stood at $150.7 million in 2021, then plunged by 50.47% to $74.7 million in 2022, then rose by 7.98% to $80.6 million in 2023, then increased by 3.38% to $83.4 million in 2024, then jumped by 89.93% to $158.3 million in 2025.
- The last three Receivables - Other figures came in at $158.3 million (Q4 2025), $83.4 million (Q4 2024), and $80.6 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 158.31 Mn |
| Dec 31, 2025 | 158.31 Mn |
| Dec 31, 2024 | 83.35 Mn |
| Dec 31, 2024 | 83.35 Mn |
| Dec 31, 2023 | 80.62 Mn |
| Dec 31, 2023 | 80.62 Mn |
| Dec 31, 2022 | 74.66 Mn |
| Dec 31, 2022 | 74.66 Mn |
| Dec 31, 2021 | 150.73 Mn |
| Dec 31, 2021 | 150.73 Mn |
| Dec 31, 2020 | 1.73 Mn |
| Dec 31, 2020 | 1.73 Mn |
| Dec 31, 2019 | 91.33 Mn |
| Dec 31, 2019 | 91.33 Mn |
| Dec 31, 2018 | 105.49 Mn |
| Dec 31, 2018 | 105.49 Mn |
| Jun 30, 2018 | 97.98 Mn |
| Jun 30, 2018 | 97.98 Mn |
| Dec 31, 2017 | 47.90 Mn |
| Dec 31, 2017 | 47.90 Mn |